{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:33:02Z","timestamp":1785418382092,"version":"3.56.0"},"reference-count":23,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Following a major service disruption across the National Health Laboratory Service, backlogged HIV viral load (VL) specimens from Limpopo province were rerouted to Groote Schuur Hospital (GSH) laboratory in the Western Cape province. During this time, an increase in low-level viraemia (LLV; 50 copies\/mL \u2013 1000 copies\/mL) was observed at the GSH laboratory, raising concerns about possible pre-analytical and analytical issues, including compromised specimen quality and possible contamination.\nObjective:\u00a0To determine whether the observed increased LLV was due to analytical errors (e.g. contamination), pre-analytical factors such as prolonged turnaround times (TAT), or underlying epidemiological differences.\nMethods:\u00a0HIV VL data from 2023\u20132024 for Limpopo and the Western Cape were analysed using Python. Viral load results were grouped into predefined categories and compared. Turnaround times were plotted and Thembisa model estimates were used to assess HIV prevalence and antiretroviral therapy (ART) coverage. Longitudinal patient-level analysis evaluated VL trends as a proxy for adherence. In addition, quality control data were evaluated at testing sites.\nResults:\u00a0Limpopo specimens showed higher LLV (20%) and lower viral suppression (&lt; 50 copies\/mL) at 70%, compared to Western Cape (13% LLV, 81% suppression), where follow-up and suppression outcomes were also higher. No clear evidence indicated that extended TAT or potential instrument contamination affected VL results significantly.\nConclusion:\u00a0The increase in LLV at GSH was linked primarily to processing specimens from Limpopo, highlighting regional differences in HIV VL result distributions. These differences probably reflect variations in ART access and adherence, rather than laboratory-related issues such as delayed TAT, sample quality, or contamination.\nWhat this study adds:\u00a0This study shows how province-specific HIV result patterns correlate with ART adherence, using a Python script to assess serial VLs and follow-up suppression. It demonstrates the value of routine data analysis in monitoring high-throughput HIV VL tests, which are often auto-released without pathologist oversight.<\/jats:p>","DOI":"10.4102\/ajlm.v14i1.2953","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:26:53Z","timestamp":1766057213000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Using data science to investigate rising HIV low-level viraemia results at Groote Schuur laboratory in South Africa"],"prefix":"10.4102","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8477-4246","authenticated-orcid":false,"given":"Mo Se","family":"Kwon","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Universiteit van Kaapstad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9401-0504","authenticated-orcid":false,"given":"Khumo O.","family":"Sematle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Universiteit van Kaapstad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-4857","authenticated-orcid":false,"given":"Lucia","family":"Hans","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-4363","authenticated-orcid":false,"given":"Stephen","family":"Korsman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Universiteit van Kaapstad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4926-6216","authenticated-orcid":false,"given":"Nei-yuan","family":"Hsiao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Universiteit van Kaapstad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-7547","authenticated-orcid":false,"given":"Diana R.","family":"Hardie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Universiteit van Kaapstad"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"ref0","unstructured":"National Health Laboratory Service. Annual report 2022\u20132023 [homepage on the Internet]. Johannesburg: National Health Laboratory Service; 2023. [cited 2024 Nov 20]. Available from: https:\/\/www.nhls.ac.za\/key-documents\/annual-reports\/"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bangalee A, Hans L, Steegen K. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021;76(10):2659\u20132665. https:\/\/doi.org\/10.1093\/jac\/dkab220","DOI":"10.1093\/jac\/dkab220"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hans L, Cassim N, Sarang S, et al. HIV viral load testing in the South African public health setting in the context of evolving ART guidelines and advances in technology, 2013\u20132022. Diagnostics (Basel). 2023;13(17): 2731. https:\/\/doi.org\/10.3390\/diagnostics13172731","DOI":"10.3390\/diagnostics13172731"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Choga OT, Lemogang GM, Choga WT, et al. High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana. J Antimicrob Chemother. 2025;80(3):767\u2013776. https:\/\/doi.org\/10.1093\/jac\/dkae472","DOI":"10.1093\/jac\/dkae472"},{"key":"ref4","unstructured":"Google Maps. Distance from Mankweng Hospital to Groote Schuur Hospital [homepage on the Internet]. 2025. [cited 2024 Nov 20]. Available from: https:\/\/www.google.com\/search?q=Google+Maps.+Distance+from+Mankweng+Hospital+to+Groote+Schuur+Hospital+2025"},{"key":"ref5","unstructured":"Abbott Molecular. Alinity m system operations manual [homepage on the Internet]. Des Plaines, IL: Abbott Molecular; 2024. [cited 2025 Oct 23]. Available from: https:\/\/content.veeabb.com\/1d09429b-8373-419f-8f1a-d28f9586863a\/99b528de-d33d-42f2-a419-3e3e181f6705\/99b528de-d33d-42f2-a419-3e3e181f6705_source__v.pdf"},{"key":"ref6","unstructured":"Johnson LF, Van Schalkwyk C, Dorrington RE. Modelling the impact of HIV in South Africa\u2019s provinces: 2025 update [homepage on the Internet]. 2025. Centre for Integrated Data and Epidemiological Research Working Paper, University of Cape Town. [cited 2024 Jun 23]. Available from: https:\/\/thembisa.org\/downloads"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Hardie D, Korsman S, Ameer S, Vojnov L, Hsiao NY. Reliability of plasma HIV viral load testing beyond 24 hours: Insights gained from a study in a routine diagnostic laboratory. PLoS One. 2019;14(7):e0219381. https:\/\/doi.org\/10.1371\/journal.pone.0219381","DOI":"10.1371\/journal.pone.0219381"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Amellal B, Murphy R, Maiga A, et al. Stability of HIV RNA in plasma specimens stored at different temperatures. HIV Med. 2008;9(9):790\u2013793. https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00632.x","DOI":"10.1111\/j.1468-1293.2008.00632.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Vandamme AM, Van Laethem K, Schmit JC, et al. Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. Eur J Clin Invest. 1999;29(5):445\u2013452. https:\/\/doi.org\/10.1046\/j.1365-2362.1999.00462.x","DOI":"10.1046\/j.1365-2362.1999.00462.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bonner K, Siemieniuk RA, Boozary A, Roberts T, Fajardo E, Cohn J. Expanding access to HIV viral load testing: A systematic review of RNA stability in EDTA tubes and PPT beyond current time and temperature thresholds. PLoS One. 2014;9(12):e113813. https:\/\/doi.org\/10.1371\/journal.pone.0113813","DOI":"10.1371\/journal.pone.0113813"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Coetzee LM, Cassim N, Glencross DK. Newly implemented community CD4 service in Tshwaragano, Northern Cape province, South Africa, positively impacts result turn-around time. Afr J Lab Med. 2022;11(1): 1376. https:\/\/doi.org\/10.4102\/ajlm.v11i1.1376","DOI":"10.4102\/ajlm.v11i1.1376"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Dawande PP, Wankhade RS, Akhtar FI, Noman O. Turnaround time: An efficacy measure for medical laboratories. Cureus. 2022;14(9):e28824. https:\/\/doi.org\/10.7759\/cureus.28824","DOI":"10.7759\/cureus.28824"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Girdwood SJ, Crompton T, Cassim N, et al. Optimising courier specimen collection time improves patient access to HIV viral load testing in South Africa. Afr J Lab Med. 2022;11(1): 1725. https:\/\/doi.org\/10.4102\/ajlm.v11i1.1725","DOI":"10.4102\/ajlm.v11i1.1725"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kleiboeker SB. Quantitative assessment of the effect of uracil-DNA glycosylase on amplicon DNA degradation and RNA amplification in reverse transcription-PCR. Virol J. 2005;2:29. https:\/\/doi.org\/10.1186\/1743-422X-2-29","DOI":"10.1186\/1743-422X-2-29"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother 2012;56:5998\u20136000. https:\/\/doi.org\/10.1128\/AAC.01217-12","DOI":"10.1128\/AAC.01217-12"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: A multicentre cohort study. Lancet Infect Dis. 2018;18(2):188\u2013197. https:\/\/doi.org\/10.1016\/S1473-3099(17)30681-3","DOI":"10.1016\/S1473-3099(17)30681-3"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1- infected patients. Antimicrob Agents Chemother. 2014;58(7):3585\u20133598. https:\/\/doi.org\/10.1128\/AAC.00076-14","DOI":"10.1128\/AAC.00076-14"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ Jr, Bosch RJ. Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. Antivir Ther. 2015;20:73\u201376. https:\/\/doi.org\/10.3851\/IMP2772","DOI":"10.3851\/IMP2772"},{"key":"ref19","unstructured":"World Health Organization. WHO recommendations [homepage on the Internet]. 2013. [cited 2025 Feb 12]. Available from: https:\/\/www.who.int\/publications"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mashele V, Marincowitz GJO, Marincowitz C. Factors influencing adherence to antiretroviral therapy among young adults in Limpopo province. S Afr Fam Pract. 2024;66(1):e1\u2013e6. https:\/\/doi.org\/10.4102\/safp.v66i1.5973","DOI":"10.4102\/safp.v66i1.5973"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nhlongolwane N, Shonisani T. Predictors and barriers associated with non-adherence to ART by people living with HIV and AIDS in a selected local municipality of Limpopo Province, South Africa. Open AIDS J. 2023;17(1):1\u20138. https:\/\/doi.org\/10.2174\/18746136-v17-230726-2023-2","DOI":"10.2174\/18746136-v17-230726-2023-2"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Drain PK, Dorward J, Bender A, et al. Point-of-care HIV viral load testing: An essential tool for a sustainable global HIV\/AIDS response. Clin Microbiol Rev. 2019;32(3):e00097\u2013e000918. https:\/\/doi.org\/10.1128\/CMR.00097-18","DOI":"10.1128\/CMR.00097-18"}],"container-title":["African Journal of Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/2953\/3409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:26:56Z","timestamp":1766057216000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/2953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/ajlm.v14i1.2953","relation":{},"ISSN":["2225-2002","2225-2010"],"issn-type":[{"value":"2225-2002","type":"print"},{"value":"2225-2010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"article-number":"a2953"}}